Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in proportion with complete resolution of a target tophus compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
The review found no eligible studies for this question.
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in proportion with complete resolution of a target tophus compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
Monthly pegloticase showed no clear difference in proportion with complete resolution of tophi compared with placebo (moderate certainty).
The review found no eligible studies for this question.